Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohns & Colitis CongressÂÂALPN101 demonstrates efficacy in treatment of chronic inflammatory bowel disease in both in vivo and in vitro models

Alpine Immune Sciences Inc. NASDAQALPN a leading clinicalstage immunotherapy company focused on developing innovative treatments for cancer and autoimmuneinflammatory diseases presented new preclinical data on its lead autoimmuneinflammatory clinical progr...